Retatrutide Shows 28 Percent Body Weight Reduction in Trials

Retatrutide produced an average 28 percent reduction in body weight during clinical testing, the largest loss recorded for any weight-loss drug to date. The medication activates three receptors—GLP-1, GIP, and glucagon—simultaneously. This mechanism differs from existing single- or dual-receptor drugs.

The weight-loss figure comes from data presented in a recent analysis by PostRowland. The same analysis noted that the drug’s potency also introduces new safety questions. No specific adverse-event rates or regulatory timelines were provided in the source material. Further studies will be required to determine long-term effects and appropriate dosing guidelines.